^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    MYD88 L265P + BRAF V600E

    i
    Other names: MYD88, MYD88 Innate Immune Signal Transduction Adaptor, Myeloid Differentiation Primary Response Protein MyD88, Myeloid Differentiation Primary Response Gene (88), Myeloid Differentiation Primary Response 88, Mutant Myeloid Differentiation Primary Response 88, MYD88D, BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threon
    Entrez ID:
    673; 4615
    Related biomarkers:
    Expression
    Mutation
    CNA
    Fusion
    Others
    over2years
    Clinicopathological features and BRAF V600E and MYD88 L265P mutation status of nodal marginal zone lymphoma (PubMed, Zhonghua Bing Li Xue Za Zhi)
    No MYD88 L265P mutation is found in NMZL. Some cases may harbor BRAF V600E mutation and yet the prevalence remains indeterminate; further researches are warranted.
    Journal • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • BCL2 (B-cell CLL/lymphoma 2) • CD20 (Membrane Spanning 4-Domains A1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD5 (CD5 Molecule) • SPN (Sialophorin)
    |
    BRAF V600E • BRAF V600 • MYD88 L265P • CD20 expression • MYD88 L265P + BRAF V600E
    over3years
    New developments in non-Hodgkin lymphoid malignancies. (PubMed, Pathology)
    Breast implant-associated anaplastic large cell lymphoma is a new provisional entity with indolent behaviour. Finally, cutaneous T-cell proliferations include a new provisional entity, primary cutaneous acral CD8-positive T-cell lymphoma, and reclassification of primary small/medium CD4-positive T-cell lymphoma as lymphoproliferative disorder.
    Review • Journal • IO biomarker
    |
    BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MYC (V-myc avian myelocytomatosis viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • CD8 (cluster of differentiation 8) • BCL6 (B-cell CLL/lymphoma 6) • CD4 (CD4 Molecule) • TP63 (Tumor protein 63)
    |
    BRAF V600E • BRAF V600 • MYD88 L265P • BCL2 expression • MYC expression • CD8 positive • BCL6 rearrangement • BCL2 rearrangement • MYD88 L265P + BRAF V600E • CD4 positive